drugset / Trial / NCT06654596
Efficacy and Safety of Telitacicept in IgAN
Recruiting
118 enrolled
Ruijin Hospital
Huashan Hospital · collabRenJi Hospital · collabRenmin Hospital of Wuhan University · collabShanghai 6th People's Hospital · collabShanghai Changzheng Hospital · collabShanghai General Hospital, Shanghai Jiao Tong University School of Medicine · collabShanghai Longhua Hospital · collabSichuan Provincial People's Hospital · collabSongjiang Hospital Affiliated to Shanghai Jiaotong University School of Medicine · collabWannan Medical College Yijishan Hospital · collabXinhua Hospital, Shanghai Jiao Tong University School of Medicine · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
A study to evaluate efficacy and safety of telitacicept in the treatment of patients with primary IgA nephropathy at high risk of progression.
Timeline
- Start
- 2024-12-06
- Primary completion
- 2026-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Prednisolone | Other / unclassified | 0.5 mg/kg | — |
| Comparator | Prednisone | Other / unclassified | 0.5 mg/kg | — |
| Subject | Telitacicept | Protein / enzyme biologic | 240 mg | — |